In 2017, Domain Therapeutics and Merck KGaA, Darmstadt, Germany, entered into collaboration and licensing agreement for the development of adenosine receptor antagonist drugs specifically designed for oncology and immuno-oncology.
Domain Therapeutics brought its expertise in GPCR medicinal chemistry and pharmacology to optimize small molecules and identify candidates on the adenosine receptor. The pharma partner supported research activities and gained worldwide rights to Domain Therapeutics’ next generation of adenosine receptor inhibitors. Under the terms of the agreement, Domain will be eligible for more than EUR 240 million in milestones, as well as undisclosed royalties (see press release).
In 2020, Domain received a development undisclosed milestone payment following Merck KGaA, Darmstadt, Germany’s decision to enter into a regulatory phase of drug development with its candidate (see press release).